He Xiangmei, Hou Lan, Wang Donghui, Yang Liu, Li Danxi, Qin Yuan, Zhang Mingkun, Zhao Ge, Zhang Huan, Zhang Juliang
Department of Thyroid and Mammary Vascular Surgery, the First Affiliated Hospital of Air Force Military Medical University, Xi'an Shaanxi, 710032, P. R. China.
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2024 Jul 15;38(7):786-792. doi: 10.7507/1002-1892.202403102.
To investigate the effectiveness of endoscopic radical mastectomy for breast cancer combined with total pectoral muscle reconstruction with breast implants.
The clinical data of 138 female patients with breast cancer who met the selection criteria between April 2019 and December 2023 were retrospectively analyzed. The mean age of the patients was 43.8 years (range, 27-61 years). The maximum diameter of the tumors ranged from 1.00 to 7.10 cm, with an average of 2.70 cm. Pathological examination showed that 108 cases were positive for both estrogen receptor and progesterone receptor, and 40 cases were positive for human epidermal growth factor receptor 2. All patients underwent endoscopic radical mastectomy for breast cancer combined with total pectoral muscle reconstruction with breast implants. The operation time, intraoperative blood loss, prosthesis size, and occurences of nipple-areola complex (NAC) ischemia, flap ischemia, infection, and capsular contracture were recorded. The Breast-Q2.0 score was used to evaluate breast aesthetics, patient satisfaction, and quality of life (including the social mental health score, breast satisfaction score, and chest pain score). Patients were divided into two groups based on the time of operation after the technique was implemented: group A (within 1 year, 25 cases) and group B (after 1 year, 113 cases). The above outcome indicators were compared between the two groups. Furthermore, based on the postoperative follow-up duration, patients were classified into a short-term group (follow-up time was less than 1 year) and a long-term group (follow-up time was more than 1 year). The baseline data and postoperative Breast-Q2.0 scores were compared between the two groups.
The average operation time was 120.76 minutes, the average intraoperative blood loss was 23.77 mL, and the average prosthesis size was 218.37 mL. Postoperative NAC ischemia occurred in 21 cases (15.22%), flap ischemia in 30 cases (21.74%), infection in 23 cases (16.67%), capsular contracture in 33 cases (23.91%), and prosthesis removal in 2 cases (1.45%). The operation time of group A was significantly longer than that of group B ( <0.05), and there was no significant difference in intraoperative blood loss, prosthesis size, and related complications between the two groups ( >0.05). All patients were followed up 3-48 months (mean, 20 months). There were 33 cases in the short-term group and 105 cases in the long-term group. There was no significant difference in baseline data such as age, body mass index, number of menopause cases, number of neoadjuvant chemotherapy cases, number of axillary lymph node dissection cases, breast cup size, degree of breast ptosis, and postoperative radiotherapy constituent ratio between the two groups ( >0.05). At last follow-up, the breast satisfaction score in the patients' Breast-Q2.0 score ranged from 33 to 100, with an average of 60.9; the social mental health score ranged from 38 to 100, with an average of 71.3; the chest pain score ranged from 20 to 80, with an average of 47.3. The social mental health score of the long-term group was significantly higher than that of the short-term group ( <0.05); there was no significant difference in breast satisfaction scores and chest pain scores between the two groups ( >0.05). No patient died during the follow-up, and 2 patients relapsed at 649 days and 689 days postoperatively, respectively. The recurrence-free survival rate was 98.62%.
Endoscopic radical mastectomy for breast cancer combined with total pectoral muscle reconstruction with breast implants has fewer complications and less damage, and the aesthetic effect of reconstructed breast is better.
探讨内镜下乳腺癌根治术联合胸肌全肌瓣乳房假体再造术的疗效。
回顾性分析2019年4月至2023年12月间符合入选标准的138例女性乳腺癌患者的临床资料。患者平均年龄43.8岁(范围27 - 61岁)。肿瘤最大直径1.00 - 7.10 cm,平均2.70 cm。病理检查显示,雌激素受体和孕激素受体双阳性108例,人表皮生长因子受体2阳性40例。所有患者均行内镜下乳腺癌根治术联合胸肌全肌瓣乳房假体再造术。记录手术时间、术中出血量、假体大小以及乳头乳晕复合体(NAC)缺血、皮瓣缺血、感染、包膜挛缩的发生情况。采用Breast-Q2.0评分评估乳房美观度、患者满意度及生活质量(包括社会心理健康评分、乳房满意度评分和胸痛评分)。根据技术实施后的手术时间将患者分为两组:A组(1年内,25例)和B组(1年后,113例)。比较两组上述结局指标。此外,根据术后随访时间将患者分为短期组(随访时间小于1年)和长期组(随访时间大于1年)。比较两组的基线数据和术后Breast-Q2.0评分。
平均手术时间120.76分钟,平均术中出血量23.77 mL,平均假体大小218.37 mL。术后发生NAC缺血21例(15.22%),皮瓣缺血30例(21.74%),感染23例(16.67%),包膜挛缩33例(23.91%),假体取出2例(1.45%)。A组手术时间显著长于B组(<0.05),两组术中出血量、假体大小及相关并发症差异无统计学意义(>0.05)。所有患者随访3 - 48个月(平均20个月)。短期组33例,长期组105例。两组患者年龄、体重指数、绝经例数、新辅助化疗例数、腋窝淋巴结清扫例数、乳房罩杯大小、乳房下垂程度及术后放疗构成比等基线数据差异无统计学意义(>0.05)。末次随访时,患者Breast-Q2.0评分中乳房满意度评分33 - 100分,平均60.9分;社会心理健康评分38 - 100分,平均71.3分;胸痛评分20 - 80分,平均47.3分。长期组社会心理健康评分显著高于短期组(<0.05);两组乳房满意度评分和胸痛评分差异无统计学意义(>0.05)。随访期间无患者死亡,2例患者分别于术后649天和689天复发。无瘤生存率为98.62%。
内镜下乳腺癌根治术联合胸肌全肌瓣乳房假体再造术并发症少、损伤小,再造乳房美观效果较好。